Nokia Corporation (ADR)(NYSE:NOK)’s third
quarter results on Thursday are likely to report a drastic drop in sales and
more erosion in market share. Next week, Microsoft will launch its Windows
Phone 8 software which Nokia has termed important for its smartphones.
The once number one phone maker has lost
both in the top end and bottom end of the market, the former to Apple and
Samsung and the latter to several Asian companies. Nokia which was the
undisputed leader in the cell phone market for 14 years, had to give up its
position in the first quarter, when Samsung sold 86 million units compared to
Nokia’s 83 million.
How
Should Investors Trade NOK Now? Find Out Here
Although Nokia has replaced the Symbian
software in its phones with Windows Phone, the transition period is expected to
be difficult for the Finland based company.
An analyst in London expects Nokia to
sell only 8 million smartphones against iPhone’s 27 million and Samsung’s 55
million.
On Tuesday, Nokia’s shares rose 9% in
the past two trading sessions and now trading higher by a penny.
Sprint not planning to buy Clearwire
Sprint Nextel Corporation(NYSE:S) is not
planning to completely take over Clearwire
Corporation(NASDAQ:CLWR), according
to sources with knowledge of the matter. This report led to Sprint’s shares
tanking 17 percent after having gained 100 percent in the past three days on
speculation of a takeover. However, shares of CLWR are up 5% this morning.
Sprint Nextel had earlier entered into a
deal with Softbank Corp. to buy 70 percent stake for $20.1 billion.
Both Softbank and Sprint can’t enter
into further deals. While Softbank
cannot do so because of bank stipulations, Sprint’s merger contract prevents it
from signing new agreements.
According
to Robert Chapman, founder of hedge fund Chapman Capital LLC , “Sprint doesn’t
need to own Clearwire now, as they already paid $900 million to lease the
spectrum they need for 2012 and 2013.” He went on to say that “Sprint may be
better off buying 700 megahertz spectrum.”
No comments:
Post a Comment